Loading patent…
AssigneeCellpep Pharma Inc.
InventorsRiad Kharrat, Kamel Mabrouk, Mohammed El-Ayeb, Herve Rochat, Jean-Marc Sabatier
Estimating the term…
Maurocalcine, a novel toxin isolated from the venom of the Tunisian chactidae scorpion Scorpio maurus palmatus, has the amino acid sequence GDCLPHLKLCKENKDCCSKKCKRRGTNIEKRCR (SEQ. ID. No. 1). It potently and reversibly modifies channel gating behaviour of type 1 ryanodine receptor (RyR1) by inducing prominent subconductance behavior. Maurocalcine and its bioactive structural analogues—preferably those containing the KKCKRR motif corresponding to part of the II-III loop of the alpha1S subunit of the voltage-dependent skeletal muscle calcium channel dihydropyridine receptor—appear to possess a therapeutic potential, notably as candidate immuno-suppressive drugs, and for the treatment of pathologies in humans that may involve a dysfunction of calcium channels.
Synthetic or recombinant Maurocalcine or a bioactive structural analogue (preferably containing the KKCKRR motif) thereof.
Use of Maurocalcine or synthetic Maurocalcine or recombinant Maurocalcine or a bioactive structural analogue (preferably containing the KKCKRR motif) thereof for the preparation of an immuno-suppressive medicament.
Use of Maurocalcine or synthetic Maurocalcine or recombinant Maurocalcine or a bioactive structural analogue (preferably containing the KKCKRR motif) thereof for the preparation of a medicament for the treatment of pathologies associated with a dysfunction of calcium channel subtypes, including ryanodine receptors.
Dependencies are inferred from the claim text.